Amid a buoyant stock market this year, the real estate industry has still remained quite volatile, weighed down by both high interest rates as well as the unknown and lingering impacts of the NARWith combined experience of covering technology companies on Wall Street and working in Silicon Valley, and serving as an outside adviser to several seed-round startups, Gary Alexander has exposure to many of the themes shaping the industry today. He has been a regular contributor on Seeking Alpha since 2017. He has ...

LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare Conference at 10:55 am ET on November 19, 2024. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following e ...

Core Insights - Compass Therapeutics is advancing its clinical-stage programs with three drugs currently in trials, including CTX-009, CTX-471, and CTX-8371, with significant milestones expected in the near future [2][3][4] Clinical Development Updates - CTX-009, a bispecific antibody targeting DLL4 and VEGF-A, has fully enrolled its Phase 2/3 trial in biliary tract cancers, with top-line data expected by the end of Q1 2025 [1][4] - A Phase 2 trial for CTX-009 in combination with chemotherapy for DLL4-positive colorectal cancer is being designed, with initiation anticipated in mid-2025 [1][3] - CTX-471 has shown promising results in a Phase 1 trial, identifying NCAM as a potential biomarker for response, with a Phase 2 trial planned for mid-2025 [1][5] - The second dosing cohort of the Phase 1 study for CTX-8371 is fully enrolled, with enrollment for the third cohort expected to begin soon [1][6] Financial Performance - For Q3 2024, Compass reported a net loss of $10.5 million, consistent with the previous year, while the net loss for the nine months ended September 30, 2024, was $34.3 million, compared to $29.1 million in the same period of 2023 [7] - Research and Development expenses for Q3 2024 were $8.6 million, slightly down from $8.8 million in Q3 2023, while R&D expenses for the nine months increased to $29.3 million from $25.7 million [7] - General and Administrative expenses rose to $3.6 million for Q3 2024, up from $3.1 million in Q3 2023, primarily due to increased stock compensation expenses [8] Cash Position - As of September 30, 2024, Compass had a cash balance of $135 million, down from $152 million at the end of 2023, providing a cash runway into Q1 2027 [9]

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...

Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style of investing are usually not interested in betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potenti ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Compass, Inc. (COMP) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual in ...

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Compass Minerals International, Inc. (NYSE: CMP) on behalf of long-term stockholders following a class action complaint that was filed against Compass Minerals on April 24, 2024 with a Class Period from November 29, 2023 to March 22, 2024. Our investigation concerns whether the board of directors of Compass Minerals have breached their fiduci ...

Compass, Inc. (COMP) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this company would post earnings of $0.01 per share when it actually produced earnings of $0.04, delivering a surprise of 300%.Over the last four quarters, the company has surpassed c ...

WESTPORT, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced today its consolidated operating results for the three months ended September 30, 2024. “Despite a dynamic macroeconomic environment, we had another great quarter,” said Elias Sabo, CEO of Compass Diversified. “Our differentiated business model and strong operating companies position us to create long-term value for all stakeholders. In the th ...